Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bendamustine hydrochloride
Brand Name Belrapzo®
Payment Category Medicare Part B
Year Introduced 2019
Type of Drug Alkylating agent
Manufacturer Eagle Pharmaceuticals
Medical Affairs Questions (date verified) 919.328.5975
Coverage & Reimbursement Questions 833.324.5322
HCPCS J9036
Billing Unit 1 mg
Medicare Payment Limit (Effective January 1, 2021) $22.27

FDA-Approved Indication(s)

  • Indicated for the treatment of patients with 1) chronic lymphocytic leukemia or 2) indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. (5/08/19)

Approved Indication(s) with Orphan Drug Status 1) Treatment of chronic lymphocytic leukemia. 2) Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)
ICD-10 Code(s) for Labeled Indication(s) Chronic lymphocytic leukemia [C91.1x]; Unspecified B-cell lymphoma [C84.1x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US